DO CUONG V purchased $32K of BIVI

SpaceX committed to a $40B lease for Nvidia chips. Xencor shares rose 20% on positive drug trial results. Surgery Partners surged 46% after a $5.7B acquisition deal. Tesla gained 6% following a Barclays upgrade. Verizon raised 2026 guidance after strong customer additions. Anthropic filed for IPO, with concerns raised about its valuation and spending. FTSE 100 gained 0.7%. Big Tech earnings and Fed decision are key focuses this week.

New to The Street Show #777 features executives from Stewards Investment Capital, BioVie (NASDAQ:BIVI), FreeCast (NASDAQ:CAST), and American Fusion (OTCQB:AMFN). BioVie reports positive long COVID and Parkinson's trial results. FreeCast discusses its media monetization technology. American Fusion presents its fusion power technology. The show airs on Bloomberg Television and YouTube.

BioVie Inc. reported that its experimental Parkinson's drug, bezisterim, improved motor and non-motor symptoms in early-stage patients with higher inflammation, according to Phase 2 SUNRISE-PD trial results. In the subgroup of 28 patients, those treated with bezisterim showed improvement, while placebo patients worsened slightly. Across all 57 patients, 25% on bezisterim saw meaningful improvement versus 4% on placebo.

BioVie Inc. (BIVI) reported Phase 2 trial results for bezisterim in early-stage Parkinson’s patients. In a subgroup with high inflammation, bezisterim improved motor and non-motor scores versus placebo. Overall, bezisterim patients were 6.25x more likely to show meaningful improvement. Adverse events were lower in the treatment group. The trial enrolled untreated patients using a hybrid design. BioVie focuses on neurological and liver disease therapies.

BioVie reported Phase 2 trial data showing bezisterim improved symptoms in Parkinson’s patients with higher platelet counts compared to placebo. Safety profiles were similar. The results were exploratory and require further Phase 3 trials for confirmation, according to the company.

BioVie Inc. (BIVI) reported Phase 2 trial results showing significant improvements in specific Long COVID patient subgroups, though the overall intent-to-treat population did not reach significance. The company plans further studies.